{"schema_version":"secwatch.filing_event.v1","accession":"0001789769-23-000004","form_type":"8-K","ticker":"TIL","cik":"0001789769","company_name":"Instil Bio, Inc.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.555401+00:00","generated_at":"2026-06-20T18:04:45.728588+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Instil Bio resumes Phase 1 trial of ITIL-306; initial data expected in 2023","bullets":["Phase 1 trial of ITIL-306 (CoStAR-TIL) for NSCLC, ovarian, and renal cancer re-opened after voluntary pause.","Initial safety, translational, and efficacy data from dose escalation cohorts expected in 2023.","Resumption follows implementation of additional quality safeguards in manufacturing process.","Company expects cash runway into 2025, excluding potential monetization of Tarzana manufacturing site.","Recent reprioritization of clinical programs and corporate restructuring completed."],"urls":{"canonical":"https://secwatch.observer/filing/0001789769-23-000004","json":"https://secwatch.observer/filing/0001789769-23-000004.json","markdown":"https://secwatch.observer/filing/0001789769-23-000004.md","text":"https://secwatch.observer/filing/0001789769-23-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789769/000178976923000004/0001789769-23-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789769/000178976923000004/til-20230109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T18:04:45.728588+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}